Nuformix updates on NXP004

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP004 programme, focused on the development of novel, proprietary, cocrystal forms of olaparib, a drug currently marketed by AstraZeneca, under the Lynparza® brand name.

Lynparza® is approved for treatment of an increasing number of cancers, achieving sales of US$2.7bn in 2021 with industry analysts forecasting annual sales of US$9.7bn by 2028. However, olaparib’s very low aqueous solubility has presented challenges historically in terms of “pill burden” and low olaprib bioavailability with Lynparza® already having been reformulated once whilst on market. In spite of reformulation, olaparib’s bioavailability in the currently marketed Lynparza® formulation remains unknown, but data indicate low and variable drug exposure in humans.

The Company has filed two patent applications covering novel forms of olaparib with the potential of protection out to 2041 and has previously demonstrated the enhanced dissolution performance of all NXP004 cocrystals versus crystalline olaparib drug substance.

Having identified two lead cocrystals for progression, the Company recently announced commencement of work to scale-up production and directly compare in-vitro dissolution performance of its lead cocrystals to the marketed Lynparza® tablet product using a biologically relevant dissolution design and with drug loading relevant to human dosing.

The Company is pleased to announce that the results from these studies demonstrate that the two lead NXP004 cocrystals selected out-perform Lynparza®, both in terms of rate and extent of dissolution and release of olaparib.

Enhancement of dissolution in the currently marketed formulation of Lynparza® resulted in improved bioavailability versus the initial marketed product. Therefore, the NXP004 programme may offer potential to further increase olaparib bioavailability. In addition, the potential simplicity of NXP004-based formulations may offer improvements in product cost-of-goods versus the currently marketed product, which requires complex manufacturing methods.

These attributes position NXP004 for applications in line-extensions for the currently marketed product, or for possible development in future first-to-generic products.

The Company will now consider the design and execution of suitable pre-clinical pharmacokinetic models to further investigate and validate NXP004’s potential for enhancing the oral absorption of olaparib. Securing these data will enable commencement of discussions with multiple potential commercialisation partners.

Further updates will be announced in due course, as appropriate.

Commenting, Dr Dan Gooding, Executive Director of Nuformix, said: I’m delighted with the results of the head-to-head dissolution studies, which exceeded my expectations and have demonstrated first-time that the lead NXP004 cocrystals offer significant scope for enhanced performance versus Lynparza®, for which biorelevant dissolution data is not in the public domain. The NXP004 cocrystals studied demonstrate some of the best dissolution performance I’ve seen from application of the technology – a step-change in dissolution performance, yet they appear to lack any of the common drawbacks that can hamper development of cocrystal-based products, which is surprising. These new data strongly support progression of the programme and we will now look to translate these enhancements into an in-vivo setting, which if successful will position the Company well for commencing partnering discussions with multiple potential partners identified.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Nuformix plc

More articles like this

Nuformix plc

Nuformix further evaluating NXP002 combination therapies now underway

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP002 programme, a proprietary new form of tranilast, being developed as a novel inhaled

Nuformix plc

Nuformix excited by prospects for the remainder of the year

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced its unaudited results for the six months ended 30 September 2022. Operational highlights (including post-period end) ·      Initial pre-clinical inhalation studies undertaken

Nuformix plc

Nuformix to host online presentation and Q&A session

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company will be hosting an online presentation and Q&A session at 5.30 p.m. GMT on Wednesday 9

Nuformix plc

Nuformix lead programme introduced to major respiratory players (VIDEO)

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP002 programme, a proprietary new form of tranilast, being developed as a novel inhaled treatment

Nuformix plc

Nuformix introduces lead programme to major respiratory players

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP002 programme, a proprietary new form of tranilast, being developed as a novel inhaled treatment

Nuformix plc

Campaign calls for diagnosis of pulmonary fibrosis

The president of the Portuguese Society of Pulmonology, António Morais, warned that patients should not underestimate symptoms and insisted on the importance of early diagnosis in fibrotic diseases, stressing that it is crucial to stop progression. The campaign

Nuformix plc

Almost half of cancer deaths are preventable

Nearly 50% of cancer deaths worldwide are caused by preventable risk factors, such as smoking and drinking alcohol, according to the largest study of the link between cancer burden and risk factors1. Using estimates of cancer cases and

Nuformix plc

PF awareness means ‘Being here for each other’ in September

From sharing stories and “going blue,” to offering yoga sessions and hosting community walks, patients and supporters are set to mark Pulmonary Fibrosis Awareness Month, held annually in September. The effort is also aimed at raising research funds

Nuformix plc

What is cancer?

Cancer is a disease in which some of the body’s cells grow uncontrollably and spread to other parts of the body.  Cancer can start almost anywhere in the human body, which is made up of trillions of cells.

Nuformix plc

Cancer warning signs

Cancer is the leading cause of death globally, the World Health Organisation says, killing almost 10 million people each year. While about one in six deaths are due to cancer, many forms of the disease can be cured if they

Nuformix plc

COVID-19 and IPF: Fundamental similarities found

An AI-guided analysis of more than 1000 human lung transcriptomic datasets found that COVID-19 resembles idiopathic pulmonary fibrosis (IPF) at a fundamental level, according to a study published July 20, 2022. In the aftermath of COVID-19, a significant number of

Nuformix plc

Nuformix progressing to robustly investigate NXP002’s efficacy

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that NXP002, a new form of tranilast and a potential novel inhaled treatment for Idiopathic Pulmonary Fibrosis, has successfully

Nuformix plc

Nuformix to continue to optimise value from its existing assets

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced its audited results for the year ended 31 March 2022. Non-executive Directors’ Statement Introduction Following the departure of

Nuformix plc

Can you have both pulmonary fibrosis and emphysema together?

Combined pulmonary fibrosis and emphysema (CPFE) is a condition that causes symptoms of both pulmonary fibrosis and emphysema. People with CPFE have both air sac destruction (seen in people with emphysema) and also scarred lung tissue of what

Nuformix plc

Virtual, in-person events planned for 2022 PFF Walk

The Pulmonary Fibrosis Foundation (PFF) is hosting its sixth annual PFF Walk fundraiser with virtual and in-person events over the next few months to raise funds and awareness in support of people living with pulmonary fibrosis. “We encourage everyone to join

Nuformix plc

Beating cancer — the role of Europe’s environment

Cancer affects the lives of many Europeans. Environmental and occupational exposure to air pollution, radon, UV radiation, chemical carcinogens, asbestos and other risks contributes significantly to the high burden of cancer in Europe. However, all environmental and occupational

Nuformix plc

Living with pulmonary fibrosis

Pulmonary fibrosis is also a term that’s used to refer to a disease that is found in the interstitium of the lungs. It falls into an even larger group of diseases called ILDs. Why? Because the scarring is found in the interstitium of

No more posts to show